Literature DB >> 28636056

Comparison of complications following tibial tuberosity advancement and tibial plateau levelling osteotomy in very large and giant dogs 50 kg or more in body weight.

Eric C Hans1, Matthew D Barnhart, Shawn C Kennedy, Steven J Naber.   

Abstract

OBJECTIVES: To analyse and compare major complications in dogs ≥50 kg undergoing tibial tuberosity advancement (TTA) or tibial plateau levelling osteotomy (TPLO) for treatment of cranial cruciate ligament disease.
METHODS: Medical records and radiographs of client-owned dogs (≥50 kg) treated for cranial cruciate ligament disease with either TTA or TPLO between January 2011 and November 2015 were reviewed. Ninety-one TTA cases and 54 TPLO cases met the study inclusion criteria. All complications within one year of surgery were recorded. Major complications were those requiring surgical revision or intervening medical therapy to resolve. Logistic regression analysis evaluated for associations with major complication occurrence. Major complications were statistically compared between TTA and TPLO treatment groups.
RESULTS: Incidence of major complications following TTA and TPLO surgery were 19.8% and 27.8%, respectively. Surgical site infection (SSI) was the single most common major complication following both TTA (15.4%) and TPLO (25.9%) surgery. There were no significant differences between TTA and TPLO treatment regarding the rate of SSI, surgical revision, or overall occurrence of major complications. Postoperative antibiotic therapy significantly reduced the risk of a major complication in all dogs ≥50 kg (p = 0.015; OR: 0.201: 95%CI: 0.055-0.737). CLINICAL SIGNIFICANCE: Major complications occurred frequently following TTA and TPLO treatment of cranial cruciate ligament disease in dogs ≥50 kg. The increased chance for SSI should be considered and postoperative antibiotic therapy is recommended.

Entities:  

Keywords:  CCLR; Canine cruciate ligament rupture; TPLO; TTA; surgical site infection; tibial plateau levelling osteotomy; tibial tuberosity advancement

Mesh:

Year:  2017        PMID: 28636056     DOI: 10.3415/VCOT-16-07-0106

Source DB:  PubMed          Journal:  Vet Comp Orthop Traumatol        ISSN: 0932-0814            Impact factor:   1.358


  6 in total

1.  Chlorhexidine shampooing of dogs the night before elective surgery: Are human recommendations applicable to veterinary medicine?

Authors:  Ömer Coskun; Sivert Viskjer
Journal:  Can J Vet Res       Date:  2022-10       Impact factor: 0.897

2.  Role of Tibial Tuberosity Fracture/Fissure through the Maquet Hole in Stifle Osteoarthritis after Porous Tibial Tuberosity Advancement in Dogs at Mid-Term Follow-Up.

Authors:  Alberto Maria Crovace; Francesco Staffieri; Donato Monopoli; Alejandro Artiles; Laura Fracassi; Antonio Crovace; Luca Lacitignola
Journal:  Vet Sci       Date:  2019-12-22

Review 3.  Tibial Plateau Leveling Osteotomy for Cranial Cruciate Ligament Rupture in Canines: Patient Selection and Reported Outcomes.

Authors:  Andy Nanda; Eric C Hans
Journal:  Vet Med (Auckl)       Date:  2019-12-27

4.  Antimicrobial prophylaxis is considered sufficient to preserve an acceptable surgical site infection rate in clean orthopaedic and neurosurgeries in dogs.

Authors:  Kirsi Johanna Välkki; Katariina Hanne Thomson; Thomas Sven Christer Grönthal; Jouni Juho Tapio Junnila; Merja Hilma Johanna Rantala; Outi Maria Laitinen-Vapaavuori; Sari Helena Mölsä
Journal:  Acta Vet Scand       Date:  2020-09-17       Impact factor: 1.695

5.  Preliminary Clinical and Radiographic Evaluation of a Novel Resorbable Implant of Polylactic Acid (PLA) for Tibial Tuberosity Advancement (TTA) by Modified Maquet Technique (MMT).

Authors:  Victoria Valiño-Cultelli; Óscar Varela-López; Antonio González-Cantalapiedra
Journal:  Animals (Basel)       Date:  2021-04-28       Impact factor: 2.752

6.  Short-term outcomes and complications of 65 cases of porous TTA with flange: a prospective clinical study in dogs.

Authors:  Cristina Bernardi-Villavicencio; Antonio Nicolas Jimenez-Socorro; Concepcion Rojo-Salvador; Javier Robles-Sanmartin; Jesus Rodriguez-Quiros
Journal:  BMC Vet Res       Date:  2020-08-10       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.